e 4031 has been researched along with Alloxan Diabetes in 1 studies
E 4031: class III anti-arrhythmia agent; structure given in UD
| Excerpt | Relevance | Reference |
|---|---|---|
| "We designed the present study to examine whether diabetes mellitus affects the antiarrhythmic effect of flecainide, a sodium channel blocker, E-4031, a potassium channel blocker, and verapamil, a calcium channel blocker, in diabetic rats." | 3.73 | Diabetes mellitus reduces the antiarrhythmic effect of ion channel blockers. ( Hayashi, Y; Ito, I; Iwasaki, M; Kamibayashi, T; Kawai, Y; Mashimo, T; Takada, K; Yamatodani, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, I | 1 |
| Hayashi, Y | 1 |
| Kawai, Y | 1 |
| Iwasaki, M | 1 |
| Takada, K | 1 |
| Kamibayashi, T | 1 |
| Yamatodani, A | 1 |
| Mashimo, T | 1 |
1 other study available for e 4031 and Alloxan Diabetes
| Article | Year |
|---|---|
Diabetes mellitus reduces the antiarrhythmic effect of ion channel blockers.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Diabetes Mellitus; Diabetes M | 2006 |